- EU sanctions against Russia: does the duty to freeze assets of listed persons also extend to their voting rights in corporations?
- Spotify, Joe Rogan and the Digital Services Act – the Sound of Issues to Come?
- The Application of the Comparator Approach by the CJEU in Gender Recognition Cases
- The Case of EncroChat and the Presumption of Innocence in EU Law
- The EU’s Media Freedom Act – Bolstering Core Union Values through the Narrow Prism of the Internal Market?
- Spotify, Joe Rogan and the Digital Services Act – the Sound of Issues to Come?
- The EU Commission’s report on new genome editing techniques: a treasure trove for sustainable CRISPR food – or a Pandora’s box?
- Will Directive 2020/1828 on the EU representative action lead to ‘better’ enforcement, as envisaged by the New Deal for Consumers?
- For EU law enforcement strategy and theory building!
- The New Pact on Migration and Asylum: a paradigm shift in regulation and enforcement?
- EU sanctions against Russia: does the duty to freeze assets of listed persons also extend to their voting rights in corporations?
- The CJEU judgments in C-117/20 bpost and C-151/20 Nordzucker: Fundamental rights as a vehicle for hybrid enforcement mechanisms?
- The EU’s response to Russia’s invasion of Ukraine: a new direction in EU defence policy or a reinforcement of military interdependence?
- Origin-labelling legislation in the EU: striking the balance between free movement and consumer protection
- Will Directive 2020/1828 on the EU representative action lead to ‘better’ enforcement, as envisaged by the New Deal for Consumers?
- The CJEU judgments in C-117/20 bpost and C-151/20 Nordzucker: Fundamental rights as a vehicle for hybrid enforcement mechanisms?
- Uitsluiting van ontvangers van buitenlandse subsidies in aanbestedingsprocedures: bezinning geboden!
- Enforcement of intellectual property rights: pioneering in private enforcement
- Towards Better Enforcement of EU Chemicals Rules: The 2020 Commission Strategy and the Registration of Chemicals
- The case of AstraZeneca’s COVID-19 vaccine and the complex enforcement of EU medicines policy